Vanguard Global Advisers
TCRX icon

Vanguard Global Advisers’s TScan Therapeutics TCRX Stock Holding History

Vanguard Global Advisers’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4K Hold
15,705
– – ﹤0.01% 3398
2026
Q1 		$15.9K Buy
+15,705
New +$16.8K ﹤0.01% 3382

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Vanguard Global Advisers's TCRX Position: Q2 2026 in Review

Vanguard Global Advisers held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 15,705 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Vanguard Global Advisers first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.9K in Q1 2026. 51 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Vanguard Global Advisers held 15,705 shares of TScan Therapeutics worth $15.4K as of Q2 2026.
  • Vanguard Global Advisers left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3398 holding.
  • Vanguard Global Advisers first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's TScan Therapeutics position peaked at $15.9K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.